Recurrent and/or metastatic thyroid cancer: therapeutic options.
Thyroid cancer is relatively rare, accounting for 0.5 - 10 cases per 100,000 individuals per year. Despite their generally favourable prognosis, patients with differentiated thyroid cancer are at risk of tumour recurrence for decades after diagnosis. The optimal management remains controversial even...
Hlavní autoři: | Karavitaki, N, Vlassopoulou, V, Tzanela, M, Tzavara, I, Thalassinos, N |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2002
|
Podobné jednotky
-
Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy.
Autor: Karavitaki, N, a další
Vydáno: (2005) -
Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
Autor: Tzanela, M, a další
Vydáno: (2004) -
Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
Autor: Tzanela, M, a další
Vydáno: (2005) -
Novel therapeutic options for recurrent metastatic salivary gland tumors: Review of ongoing clinical trials
Autor: Avinash Pandey, a další
Vydáno: (2018-01-01) -
THERAPEUTIC OPTIONS FOR INVASIVE BREAST CANCER
Autor: Ganusevich O. N., a další
Vydáno: (2019-05-01)